JP2016528174A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528174A5
JP2016528174A5 JP2016517040A JP2016517040A JP2016528174A5 JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5 JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5
Authority
JP
Japan
Prior art keywords
item
cdp
conjugate
jak inhibitor
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016517040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/040230 external-priority patent/WO2014194195A2/en
Publication of JP2016528174A publication Critical patent/JP2016528174A/ja
Publication of JP2016528174A5 publication Critical patent/JP2016528174A5/ja
Pending legal-status Critical Current

Links

JP2016517040A 2013-05-31 2014-05-30 治療的送達用のシクロデキストリンベースのポリマー Pending JP2016528174A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829797P 2013-05-31 2013-05-31
US61/829,797 2013-05-31
PCT/US2014/040230 WO2014194195A2 (en) 2013-05-31 2014-05-30 Cyclodextrin-based polymers for the therapeutic delivery

Publications (2)

Publication Number Publication Date
JP2016528174A JP2016528174A (ja) 2016-09-15
JP2016528174A5 true JP2016528174A5 (enExample) 2017-07-13

Family

ID=51985801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517040A Pending JP2016528174A (ja) 2013-05-31 2014-05-30 治療的送達用のシクロデキストリンベースのポリマー

Country Status (5)

Country Link
US (2) US20140357557A1 (enExample)
JP (1) JP2016528174A (enExample)
AU (1) AU2014273983A1 (enExample)
CA (1) CA2913752A1 (enExample)
WO (1) WO2014194195A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105924444B (zh) * 2015-03-11 2019-06-18 苏州晶云药物科技股份有限公司 Jak抑制剂的晶型及其制备方法
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
JP6878418B2 (ja) * 2015-09-28 2021-05-26 シーティーアイ・バイオファーマ・コーポレーションCTI BioPharma Corp. 移植片拒絶反応の処置方法
CN108472308A (zh) * 2015-10-20 2018-08-31 埃默里大学 应答指导型hcv疗法
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
CA3045666A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN110418796A (zh) 2017-03-08 2019-11-05 施万生物制药研发Ip有限责任公司 托法替尼(tofacitinib)的葡萄糖苷酸前药
CN110475565A (zh) * 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
EP3609903A1 (en) 2017-05-23 2020-02-19 Theravance Biopharma R&D IP, LLC Thiocarbamate prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
EP3720444A4 (en) 2017-11-03 2022-01-26 Osteoanalgesia, LLC DRUG DELIVERY SYSTEM FOR TREATING A DISEASE
US20210015933A1 (en) * 2018-03-30 2021-01-21 Seikagaku Corporation Bioactive carboxylic acid type compound-polymer conjugate, and method for manufacturing the same
US10912759B2 (en) * 2018-05-17 2021-02-09 William Andrew Clark Topical gel compositions for the treatment of Staphylococcal infections
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110403944A (zh) * 2019-08-07 2019-11-05 中南大学湘雅医院 Decernotinib在制备治疗银屑病的外用药物中的应用、药物及制备方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
KR20240027732A (ko) * 2021-07-20 2024-03-04 코발 바이오파마 (상하이) 컴퍼니 리미티드 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용
US20240299295A1 (en) * 2021-09-09 2024-09-12 Biora Therapeutics, Inc Aqueous formulations of tofacitinib and tofacitinib salts
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
WO2023244611A1 (en) * 2022-06-13 2023-12-21 Emory University Uses of jak inhibitors in the management of inflammation-associated depression and central nervous system (cns) pathologies
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996612A4 (en) * 2006-03-03 2010-10-20 Univ Kingston COMPOSITIONS FOR THE TREATMENT OF CANCER
BR112012012210B8 (pt) * 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
WO2012003457A1 (en) * 2010-07-01 2012-01-05 Mtm Research Llc Anti-fibroblastic fluorochemical emulsion therapies
US20120213854A1 (en) * 2010-09-30 2012-08-23 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors

Similar Documents

Publication Publication Date Title
Birke et al. Polypeptoid-block-polypeptide copolymers: Synthesis, characterization, and application of amphiphilic block copolypept (o) ides in drug formulations and miniemulsion techniques
ES2510396T3 (es) Direccionamiento a células de cáncer usando nanopartículas
CN101541347B (zh) 药物载体、其合成及其使用方法
Moore et al. Multifunctional polymer‐coated carbon nanotubes for safe drug delivery
ES2525257T3 (es) Composiciones de ciclopolisacárido y de bendamustina
JP2016153410A5 (enExample)
JP2017511322A5 (enExample)
JP2015528002A5 (enExample)
JP2017505104A5 (enExample)
JP2014531476A5 (enExample)
JP2011523643A5 (enExample)
JP2011530597A5 (enExample)
JP2019523761A5 (enExample)
JP2001514167A5 (enExample)
US20220054659A1 (en) Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents
JP2010513441A5 (enExample)
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
JP2020519676A5 (enExample)
JPWO2012067138A1 (ja) 新規なシチジン系代謝拮抗剤の高分子誘導体
CN102174579B (zh) 可还原降解的梳型高分子基因载体及其制备方法
US20170042828A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
RU2018128032A (ru) Полимеры на основе циклодекстрина, способы, композиции и применение
JP2016511777A5 (enExample)
JP2011506296A5 (enExample)
JP2021504302A5 (enExample)